The total number of shares in Biovitrum AB (publ) as per 30 January 2009 amounts to in total 50,098,782 shares, whereof 49,814,782 common shares and 284,000 class C shares, corresponding to in total 49,843,182 votes. The increase in the number of shares and votes results from Biovitrum's asset purchase agreement entered into with Amgen Inc." For more information please contact: Biovitrum Göran Arvidson, CFO Phone: +46 8 697 23 68 Erik Kinnman, VP Investor Relations Phone: +46 8 697 21 50 [email protected] About Biovitrum Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.3 billion and around 500 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com. Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on January 30, 2009 at 11:30 a.m. CET.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.